Publication Date
6-18-2020
Journal
Current Atherosclerosis Reports
DOI
10.1007/s11883-020-00856-6
PMID
32556778
PMCID
PMC7301047
PubMedCentral® Posted Date
6-18-2020
PubMedCentral® Full Text Version
Post-print
Published Open-Access
yes
Keywords
Adolescent, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Child, Cholesterol, LDL, Denervation, Eicosapentaenoic Acid, Electronic Nicotine Delivery Systems, Female, Heart Failure, Heterocyclic Compounds, 2-Ring, Humans, Hyperlipoproteinemia Type II, Hypertension, Kidney, Male, Middle Aged, Pyrimidines, Randomized Controlled Trials as Topic, Smoking Cessation, United States, Young Adult, Cardiovascular disease prevention, Risk factor assessment, ASCVD risk reduction
Abstract
PURPOSE OF REVIEW: The review highlights selected studies related to cardiovascular disease (CVD) prevention that were presented at the American College of Cardiology 2020 Virtual Scientific Session (ACC.20)/World Cardiology Congress (WCC).
RECENT FINDINGS: The studies reviewed include clinical trials on the efficacy and safety of alirocumab (Study in Participants with Homozygous Familial Hypercholesterolemia [ODYSSEY HoFH]) and evinacumab in the treatment of homozygous familial hypercholesterolemia (HoFH); Evaluating the Efficacy of E-cigarettes for Smoking Cessation (E3); the use of renal denervation in the treatment of hypertension (SPYRAL HTN-OFF MED PIVOTAL); and the assessment of vericiguat in the treatment of heart failure (A Study of Vericiguat in Participants with Heart Failure with Reduce Ejection Fraction [VICTORIA]). In addition, results from the pooled analysis of phase III trials on inclisiran and secondary analysis examining eicosapentaenoic acid levels and cardiovascular outcomes from the Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial (REDUCE-IT) were included. Finally, we discuss studies examining the use of polygenic risk score with low density lipoprotein cholesterol (LDL-C) and systolic blood pressure (SBP) on lifetime cardiovascular risk. The studies presented at the ACC.20/WCC represent notable contributions in the field of CVD prevention.